Data-first IR operating system for biotech.
Turn your pipeline updates into a single, consistent source of truth. Build quarterly materials, launch briefs, and call prep that show what changed and why — backed by your own documents, with version control and evidence.
Get Early AccessData-first IR OS for biotech: turn your updates into a unified, consistent "source-of-truth" with version control and diff history.
Build quarterly updates, launch briefs, and data release playbooks — so it's clear what changed and why, grounded in your documents.
Every claim gets an Evidence Pack, so analysts see the primary source and spend less time debating "where did this come from."
Integrity & Consistency monitor: flags wording drift, vague timelines, protocol changes, and gaps before they become analyst questions.
Launch Brief Generator: structured launch scorecard with pricing/access, demand drivers, and "questions for next quarter" — versioned over time.
Q&A prep: expected questions + evidence-backed answers + "data release playbook" (what question should the data close, what context is mandatory).
Not a "text generator" — it's disclosure quality control: less chaos, more communication predictability, better version discipline.
Result: higher trust in execution, less "opacity discount", easier to maintain long-term reputation and attract generalist capital.
Three outputs that transform IR workflow
Structured, evidence-backed materials that build analyst trust and reduce communication risk.
IR Update Builder + Launch Brief
Publish-Ready Packages
Ready-made drafts for quarterly updates and launch reports: what's new, what changed, what's not disclosed, plus a launch scorecard with pricing/access/demand drivers — all versioned over time.
- Ready draft: "what's new" + "what changed" + "what's not disclosed"
- Launch Brief: scorecard (net sales, access, gross-to-net, demand) + questions for next quarter
- Data release playbook: what question should the data close, what context is mandatory
- IR tone & language: careful, no overcommitments, no speculation
- Export to Word / Slides / PDF + separate Evidence Pack for internal use
ACM-202 (IBD): Phase 3 topline data expected 1H 2026. PDUFA date set for March 15, 2026.
ACM-101 timeline updated: "2H 2025" → "1H 2026" (Type B meeting feedback incorporated).
Access: formulary wins 3/5 major PBMs
Demand: +18% QoQ new starts
Gross-to-net: not disclosed
Disclosure, Consistency & Integrity Monitor
Internal Quality Control
A timeline of your own statements across key topics, with flags for language drift, gaps, and protocol/data integrity notes — strictly with citations, descriptive language only, no accusations.
- Disclosure timeline by topics: safety, regulatory, timelines, CMC, financing, access/pricing
- Consistency checks: timeline drift, stage changes, vanished/new topics
- Q&A answer-quality tags (direct / partial / evasive) as diagnostic tool
- Protocol/data integrity notes: amendments, sample size changes, IDMC, exclusions — if disclosed
- Disclosure scorecard: what's disclosed vs what's still "unknown" per program
Q3: "expect readout 2H 2025"
Q4: "we aim for 1H 2026" ← softer
Q4: sample size re-estimation mentioned (first time).
No material change in safety language across Q3-Q4.
Investor Q&A Pack
For Calls & Follow-ups
Top questions that logically follow from diffs, risks, and gaps — with evidence-backed draft answers, a "must clarify" checklist, and FAQ for analysts (including runway, key risks, timelines).
- Top questions that logically arise from diffs, risks, and gaps
- Evidence-backed answer drafts + links to sources / slides
- FAQ for analysts: runway, key risks, timelines, standard questions
- 1-pager: "what must be clarified" and "what not to leave ambiguous"
- Integrity-aware: flags where Q&A answers were previously evasive/partial
Why disclosure quality is a strategic asset
Reduce "opacity discount"
When analysts can't trace what changed and why, they discount your stock. We make your communications verifiable, consistent, and versioned.
Fewer surprise questions
Q&A prep from actual diffs, gaps, and integrity flags means you're ready for the questions analysts will logically ask — before they ask.
Catch drift before analysts do
Consistency monitoring flags when timelines softened, topics dropped, or protocol details appeared for the first time — so you proactively address them.
Build long-term trust
Systematic evidence-backed communication builds the execution reputation that attracts generalist capital back to biotech.
This is not a "text generator"
What we DON'T do
- ✕Generate marketing copy or spin
- ✕Make up data or extrapolate beyond source
- ✕Replace legal or compliance review
- ✕Give investment advice or predict outcomes
- ✕Accuse or diagnose — only describe what changed
What we DO
- Structure your existing disclosures with version control
- Track what changed, where it was said, and how language evolved
- Flag inconsistencies, gaps, and protocol changes
- Generate launch scorecards from disclosed metrics only
- Prepare evidence-backed Q&A materials + data release playbooks
Faster quarterly update prep
Claims traceable to source
Fabricated statements
Q&A pack + launch brief export
Control your disclosure. Build trust systematically.
Join the early access list — structured updates, launch briefs, consistency monitoring, and evidence-backed Q&A prep for your next call.
No spam. No credit card. Just early access to the product.